Varisacumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVarisacumab
Drug Alias NameApaginR-84GNR-011AT-001-IBCG
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPeregrineUniversity of Texas Southwestern Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterAffitechPeregrine
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A